BBI Brickell Biotech, Inc.

Brickell Biotech, Inc. engages in the development of prescription therapeutics for treatment of skin diseases. Its product pipeline includes potential novel therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

$0.32
As of 11/26/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1999
Outstanding shares:  115,048,346
Average volume:  3,115,073
Market cap:   $37,655,324
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    10802T105
ISIN:        US10802T1051
Sedol:      
Valuation   (See tab for details)
PE ratio:   -0.90
PB ratio:   1.41
PS ratio:   115.15
Return on equity:   -204.19%
Net income %:   -12,468.50%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy